First multi-gene expression profile to predict efficacy of DNA damaged therapies for ER negative breast cancer
-
Quantitative detection for DNA recombination repair defects
-
Independently predict the prognosis and efficacy of DNA damaged therapies
-
Original patent of Professor Connell, University of Chicago
-
Exclusive worldwide license
-
Duplex one-step RT-qPCR reaction
-
Good amplification efficiency
-
Minimum detection limit (10 copies)
-
Convenient calculation formula
-
Cell line and clinical verified
-
Suitable for surgery or puncture biopsy paraffin-embedded (FFPE) sections , 5μm/ 7 pieces
-
Suitable for a variety of PCR instruments (e.g. Light Cycler 480II, ABI 7500, Agilent Mx3000P, etc.)